Latest Breaking News On - சீனா வாழ்க்கை சுகாதாரம் நிதி - Page 1 : comparemela.com

Canada s Virogin raises $120m led by China Life; to use proceeds for Shanghai R&D centre

Canada s Virogin raises $120m led by China Life; to use proceeds for Shanghai R&D centre
dealstreetasia.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from dealstreetasia.com Daily Mail and Mail on Sunday newspapers.

British columbiaChris huangWilliam jiaLinden asset groupChina life healthcare fundChina structural reform fundShenzhen capital groupVirogin biotechChina lifeChina life healthcareChina securitiesPanlin capitalChina structural reformபிரிட்டிஷ் கொலம்பியாகிறிஸ் ஹுவாங்லிண்டன் சொத்து குழு

China s medical equipment provider Jenscare secures funding co-led by GL Ventures

Primavera Capital, which had led an undisclosed Series B round funding in Jenscare, acted as the co-lead investor in the latest round.

Hong kongChina life healthcare fundAgricultural bankNingbo jenscare biotechnologyco ltdChina securities regulatory commission onJenscare scientificNingbo jenscare biotechnologycoHillhouse capitalChina asset managementForebright capitalFuturex capitalChina securities regulatory commissionஹாங் காங்சீனா வாழ்க்கை சுகாதாரம் நிதிசீனா பத்திரங்கள் ஒழுங்குமுறை தரகு ஆன்ஹில்ஹவுஸ் மூலதனம்

GeneQuantum Raises Hundreds of Millions RMB in Series C Funding

GeneQuantum Raises Hundreds of Millions RMB in Series C Funding News provided by Share this article Share this article SUZHOU, China, May 18, 2021 /PRNewswire/ GeneQuantum Healthcare (Suzhou) Co., Ltd. (hereinafter GeneQuantum ) announced the completion of Series C fund raising of several hundreds of millions RMB. This series of fund raising is led by China Life Private Equity Investment, jointly by PICC Capital Equity Investment, Sunshine Guojian and Suzhou Wuzhong Biomedicine Industrial Park Investment. The current fund raising will provide a solid financial foundation to GeneQuantum for its global clinical development and pipeline expansion of next generation site-specific bioconjugates. Since its establishment, GeneQuantum has focused on the development of innovative bioconjugate drugs represented by Antibody-Drug-Conjugate (ADC). We possess highly differentiated ADC technology platforms, including enzyme catalyzed site-specific conjugation technology, innovative li

Guo jianGang qinLerming pharmaLeidi zhangInnovation fundHealthcare fundInvestment co ltdGenequantum healthcare suzhou co ltdRendong holdingSuzhou direct investment fundChina life health foundationCapital equity investment company limitedChina life healthcare fundSector fundTechnological development zoneWuzhong biomedicine industrial park investment co ltd

DCP, Sequoia China lead Series B round for medical devices firm Valgen

DCP, Sequoia China lead Series B round for medical devices firm Valgen Source: Valgen Medtech May 6, 2021 Greater China-focused private equity firm DCP and tech investment bellwether Sequoia Capital China have co-led a Series B round of financing for Valgen Medtech, a developer of treatment technologies for heart diseases in China. The investment size is said to be “hundreds of millions of US dollars.” Lake Bleu Capital, a healthcare-focused asset management platform; Chinese transcatheter heart valve medical devices maker Venus Medtech; China Life Healthcare Fund, an investment vehicle of Beijing-based insurer China Life Insurance; Hong Kong’s healthcare investor Ascendum Capital participated in the round. Existing shareholder Qiming Venture Partners re-upped in the round.

Hong kongValgen medtechVenus medtechChina life healthcare fundGreater china focusedSequoia capital chinaBleu capitalChina life insuranceAscendum capitalQiming venture partnersDinova medtechHangzhou cityBiotrack capitalஹாங் காங்வெள்ளி மெதிதேச்சீனா வாழ்க்கை சுகாதாரம் நிதி